Abstract
Systemic sclerosis (SSc) pregnant women show a high frequency of premature births and occurrence of renal crisis. Some evidences showed the role of L-arginine in the prevention and treatment of preeclampsia. Here, we report our experience on the effect of L-arginine treatment in four consecutive SSc pregnant women. Two patients, who have planned the pregnancy, were treated with oral L-arginine; both delivered healthy babies without any prenatal complications. The other two, with high risk of pregnancy complications because of severe lung involvement and type 1 diabetes, respectively, underwent i.v. L-arginine: patient 3 had a premature delivery of a 2-kg healthy baby, while patient 4 developed preeclampsia and, at the 28th week, delivered a 1,050-g girl. The neonate had severe respiratory distress syndrome complicated by severe infection and died at day 28. Although limited, our pilot study suggests that L-arginine may be a useful therapeutic agent in pregnant SSc women.
This is a preview of subscription content, log in via an institution to check access.
References
Medsger TA Jr. (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions, 14th ed. Lippincott Williams & Wilkins, Philadelphia, pp 1590-1624
Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine 81:139–153
Steen VD (1999) Pregnancy in women with systemic sclerosis. Obstet Gynecol 94:15–20
Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M (2008) Pregnancy in systemic sclerosis. Rheumatology 47(Suppl 3):iii16–iii18
Palmer RM, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664–666
Facchinetti F, Longo M, Piccinini F et al (1999) L-Arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Invest 6:202–207
Staff AC, Berge L, Haugen G et al (2004) Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. Acta Obstet Gynecol Scand 83:103–107
Rytlewsky K, Olszanecki R, Lauterbach R, Grzyb A, Basta A (2006) Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin Pharmacol Toxicol 99:146–152
No authors listed (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
Carbonne B, Macé G, Cynober E et al (2007) Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma. Am J Obstet Gynecol 197:6–7
Xiao XM, Li LP (2005) L-Arginine treatment for asymmetric fetal growth restriction. Int J Gynecol Obstet 88:15–18
Baylis C (2006) Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2:209–220
Junbao D, Hui Y, Bing W et al (2005) Effect of l-arginine on collagen of high flow-induced pulmonary arterial remodelling. Circ J 69:603–608
Takagi K, Kawaguchi Y, Hara M (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134:538–544
Pernow J, Bohm F, Beltran E et al (2003) L-Arginine protects from ischemia–reperfusion-induced endothelial dysfunction in humans in vivo. J Appl Physiol 95:2218–2222
Rembold CM, Ayers CR (2003) Oral l-arginine can reverse digital necrosis in Raynaud’s phenomenon. Mol Cell Biochem 244:139–141
Collier SR, Casey DP, Kanaley JA (2005) Growth hormone responses to varying doses of oral arginine. Growth Horm IGF Res 15:136–139
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giuggioli, D., Colaci, M., Sebastiani, M. et al. L-Arginine in pregnant scleroderma patients. Clin Rheumatol 29, 937–939 (2010). https://doi.org/10.1007/s10067-010-1396-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1396-4